Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials
      QxMD      Google Scholar   
Citation:
Lancet Oncol. vol 16 (7) 848-58
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10-CA-69651, U10-CA-37377, 021039, N01 CA032102, U10 CA077202, CA077202, U10 CA021115, U10 CA012027, U10 CA180821, CCSRI 015469, U10-CA-69974, U10-CA-12027, U10 CA069651, U10 CA032102, U10 CA016116, U24 CA075362, U10 CA069974, CA21115, CA180821, U10 CA037377, CA16116  
Corr. Author:
 
Authors:
                                           
Primary Study
IBCSG-24-02 (SOFT-TEXT)
Secondary Studies:
Phases:
3
Keywords:
adjuvant therapy, aromatase inhibitor, breast cancer, endocrine therapy, exemestane, GnRH agonist, ovarian function suppression, premenopausal, quality of life, sexual functioning, tamoxifen, triptorelin